BioSpace News Archive

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, presented durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial at the virtual Connective Tissue Oncology Society (CTOS) annual meeting.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced a clinical update on omburtamab for the treatment of diffuse intrinsic pontine glioma (“DIPG”).

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the 2020 Robert A. Pritzker Prize for Leadership in Parkinson’s Research to Caroline Tanner , MD, PhD, professor of neurology at the Weill Institute for Neurosciences, University of California, San Francisco . The Prize recognizes researchers who make exceptio

Neuropathix, Inc. (OTCQB: NPTX), formerly Kannalife, Inc. (the “Company” or “Neuropathix”), a socially responsible pain management life sciences company, announced today it has entered into a binding letter of intent to acquire a suite of sulfamide-containing neuroprotective compounds containing substructures known to produce anticonvulsant activity, as a means to provide both neuroprotection and anticonvulsant activity in the same drug candidate.

- Dr. Desai has over twenty-five years of hematology and oncology-focused clinical development and medical affairs experience, including the successful launches of targeted therapies, monoclonal antibodies, and PARP inhibitors

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of Directors

Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources. Patrizio is an experienced human resources leader with broad expertise at dynamic high-growth companies, both large and small, including Agios Pharmaceuticals, Lilly, and Procter &a

Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced the appointment of Guangping Gao, Ph.D., as Chief AAV Scientific Advisor.

Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked number 403 on Deloitte’s Technology Fast 500